Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofarabine + cytarabine with reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia in primary treatment failure
2009-015176-10Phase 2Active
- Sponsor
- CHU de Nantes
- Start
- Nov 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of clofarabine and cytarabine in acute myeloid leukemia (AML), sponsored by CHU de Nantes. Primary endpoint: Two-year overall survival. Started Nov 2009; status: active.
02
Drugs
clofarabinecytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2009-015176-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015176-10.